Financiere des Professionnels Fonds d investissement inc. Has $1.04 Million Stock Position in Medpace Holdings, Inc. $MEDP

Financiere des Professionnels Fonds d investissement inc. lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 176.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,026 shares of the company’s stock after purchasing an additional 1,294 shares during the period. Financiere des Professionnels Fonds d investissement inc.’s holdings in Medpace were worth $1,042,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in MEDP. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Employees Retirement System of Texas acquired a new position in shares of Medpace during the 2nd quarter worth about $36,000. IFP Advisors Inc increased its stake in shares of Medpace by 223.3% during the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after purchasing an additional 134 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Medpace by 5,075.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after purchasing an additional 203 shares during the period. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in Medpace by 514.3% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock valued at $67,000 after purchasing an additional 180 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the sale, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This represents a 42.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 387,925 shares of company stock valued at $233,386,647. 20.30% of the stock is owned by company insiders.

Medpace Trading Up 1.7%

NASDAQ:MEDP opened at $571.02 on Friday. The stock has a 50 day simple moving average of $579.51 and a 200 day simple moving average of $490.69. The stock has a market cap of $16.09 billion, a P/E ratio of 39.93, a PEG ratio of 1.92 and a beta of 1.43. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. During the same quarter last year, the business earned $3.01 EPS. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

MEDP has been the topic of a number of recent analyst reports. Jefferies Financial Group boosted their price target on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research report on Tuesday, September 9th. Cowen reissued a “sell” rating on shares of Medpace in a report on Friday, October 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. TD Cowen raised their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. Finally, Mizuho lifted their price objective on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, Medpace has an average rating of “Hold” and an average target price of $490.82.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.